[Conference presentation] Presenting the AD/PD™ 2026 International Conference on Alzheimer’s and Parkinson’s Diseases

Sysmex Corporation will present the latest data on the development of blood-based biomarkers for Alzheimer's Disease at International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™ 2026) to be held from March 17^th to 21^st, 2026 in Copenhagen, Denmark.

[Poster presentation]

Session	Subject	Presenter (Affiliation)
Theme A: β-Amyloid Diseases SHIFT 01-454^*1	Development of a fully automated plasma p-Tau205 immunoassay demonstrating high concordance with an immunoprecipitation mass spectrometry assay March 17^th (CET)	Kengo Ishiki (Sysmex corporation)
Theme A: β-Amyloid Diseases SHIFT 02-412^*2	Development of predictive models for amyloid positivity using routine health check-up items in older Japanese adults March 19^th (CET)	Shun Murakami (Sysmex corporation)
Theme A: β-Amyloid Diseases SHIFT 02-365^*3	Blood-based prediction of CSF amyloid pathology using plasma p-Tau217 and p-Tau217/Aβ42 ratio in the SPIN cohort March 19^th (CET)	Yuko Mori (Sysmex R&D Center Europe GmbH)

Session

Subject

Presenter
(Affiliation)

Theme A: β-Amyloid Diseases
SHIFT 01-454^*1

Development of a fully automated plasma p-Tau205 immunoassay demonstrating
high concordance with an immunoprecipitation mass spectrometry assay

March 17^th (CET)

Kengo Ishiki
(Sysmex corporation)

Theme A: β-Amyloid Diseases
SHIFT 02-412^*2

Development of predictive models for amyloid positivity using
routine health check-up items in older Japanese adults

March 19^th (CET)

Shun Murakami
(Sysmex corporation)

Theme A: β-Amyloid Diseases
SHIFT 02-365^*3

Blood-based prediction of CSF amyloid pathology using plasma p-Tau217 and
p-Tau217/Aβ42 ratio in the SPIN cohort

March 19^th (CET)

Yuko Mori
(Sysmex R&D Center Europe GmbH)

[Poster Presentation by Prof. Charlotte Teunissen, Amsterdam UMC]

Session	Subject
Theme A: β-Amyloid Diseases SHIFT 02-431^*4	High diagnostic performance of the random-access HISCL p-Tau217, Aβ42 and Aβ40 plasma assays in detecting amyloid pathology across clinical stages March 19^th (CET)

Session

Subject

Theme A: β-Amyloid Diseases
SHIFT 02-431^*4

High diagnostic performance of the random-access HISCL p-Tau217, Aβ42 and Aβ40 plasma assays in detecting
amyloid pathology across clinical stages

March 19^th (CET)

Terminology
*1 Co-presentation with Eisai Co., Ltd.
*2 Co-presentation with Hirosaki University
*3 Co-presentation with Hospital de la Santa Creu i Sant Pau, Spain
*4 Co-presentation with Amsterdam UMC

Information contained in the news and event is current as of the date of the announcement,
but may be subject to change without prior notice.

Back to "News / Event"